Transaction · 0001193125-26-382474

Maduck Sean

Maduck Sean, SR, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 2281.000000 shares for an estimated $263710.52. Reported holdings after the transaction were 9755.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
CORTCORCEPT THERAPEUTICS INC
Trade date
Sep 01, 2026
Filing date
Sep 04, 2026
View on SEC Insider profile
Estimated value-$263kShares × reported price
Shares traded2.28k$115.61 per share
Holdings after9.75kDirect
% of reported position traded18.95%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 12,036 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CORT price since this filing

Daily closing prices, with the filing date and available return windows
CORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +2.6%1w ago +10.0%1d ago +1.5%
Returns since7d +1.0%30d +4.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-382474
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 04, 2026, 01:16 AM · 3d delay
Shares
2,281 sh
$115.61 per share
Estimated value
-$263k
Computed from shares × price
Holdings after
9,755 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to th…

  2. F2

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

  3. F3

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each…

  4. F4

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at eac…

  5. F5

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each…

  6. F6

    The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…

  7. F7

    In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

  8. F8

    Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…

  9. F9

    These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

  10. F10

    The closing price on September 1, 2026 was used to calculate the withholding obligation.

  11. F11

    Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the…

  12. F12

    Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

  13. F13

    Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.

  14. F14

    Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

  15. F15

    Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

  16. F16

    Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

  17. F17

    Fully exercisable.

Original filing · 0001193125-26-382474
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CORT